|Bid||213.50 x 800|
|Ask||213.67 x 900|
|Day's Range||213.20 - 215.30|
|52 Week Range||210.28 - 276.69|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||21.66|
|Earnings Date||Oct 26, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||7.04 (3.30%)|
|Ex-Dividend Date||Aug 16, 2021|
|1y Target Est||248.18|
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.
Amgen (NASDAQ:AMGN) will present at the Cantor Global Healthcare Conference at 2:00 p.m. ET on Monday, Sept. 27, 2021. Susan Sweeney, senior vice president, Global Marketing, Access and Capabilities and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
Amgen (NASDAQ: AMGN) today released the 8th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare system. To access the full report, visit: www.amgenbiosimilars.com/commitment/trends-report.